Stroke

|

1

AstraZeneca’s Brilinta with Aspirin Reduces Heart Related Events in Late Trials

AstraZeneca reported positive phase 3 trial results of Brilinta (ticagrelor) plus aspirin, which reduced the relative risk of cardiovascular events …

| | |